Evidence map›Paper›PMID 39242461›Full record

ReviewTherapeutic innovation & regulatory science2024

Delta Inflation, Optimism Bias, and Uncertainty in Clinical Trials.

Charles C Liu, Peiwen Wu, Ron Xiaolong Yu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Therapeutic innovation & regulatory science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Charles C LiuDepartment of Biostatistics, Gilead Sciences, 333 Lakeside Drive, Foster City, CA, 94404, USA. cliu17@gilead.com.
Peiwen WuDepartment of Biostatistics, Gilead Sciences, 333 Lakeside Drive, Foster City, CA, 94404, USA.
Ron Xiaolong YuDepartment of Biostatistics, Gilead Sciences, 333 Lakeside Drive, Foster City, CA, 94404, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The phenomenon of delta inflation, in which design treatment effects tend to exceed observed treatment effects, has been documented in several therapeutic areas. Delta inflation has often been attributed to investigators' optimism bias, or an unwarranted belief in the efficacy of new treatments. In contrast, we argue that delta inflation may be a natural consequence of clinical equipoise, that is, genuine uncertainty about the relative benefits of treatments before a trial is initiated. We review alternative methodologies that can offer more direct evidence about investigators' beliefs, including Bayesian priors and forecasting analysis. The available evidence for optimism bias appears to be mixed, and can be assessed only where uncertainty is expressed explicitly at the trial design stage.

Indexed as

Bayes TheoremClinical Trials as TopicOptimismBiasHumansResearch DesignUncertaintyAssuranceBrier scoreEquipoisePrior-data conflictProbability of success

Identifiers

PMID39242461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.